Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating empasiprubart for adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a condition causing nerve inflammation and muscle weakness. This Phase 3 randomized, double-blinded, placebo-controlled study aims to demonstrate the efficacy and safety of empasiprubart in treating CIDP. The study is sponsored by argenx and includes adults diagnosed with typical or variant forms of CIDP who have active disease and residual disability. Participants are randomly assigned in part A to receive either empasiprubart or a placebo by intravenous infusion for 24 weeks 6 months. After part A, all participants enter part B, where everyone receives empasiprubart for 96 weeks 24 months. Participants who received empasiprubart in part A will receive a placebo infusion once during part B to maintain blinding. Throughout the study, participants will undergo regular assessments including the adjusted Inflammatory Neuropathy Cause and Treatment aINCAT score, grip strength measurements, muscle strength evaluations, and quality of life questionnaires. Researchers will monitor changes from baseline in motor function, disability, and symptom severity up to 24 weeks in part A and continue evaluations through part B. Safety measures include tracking adverse events and immune responses. The total participation duration can last up to 120 weeks approximately 30 months.
Actively Recruiting
Researchers are evaluating the efficacy of claseprubart DNTH103 compared to placebo in adults with chronic inflammatory demyelinating polyneuropathy CIDP. This Phase 3 study aims to assess whether claseprubart can improve outcomes in participants with typical or variant forms of CIDP, including motor or multifocal types. The study is sponsored by Dianthus Therapeutics and involves several treatment periods to carefully measure the drugs impact. The study consists of multiple parts Part A includes an open-label phase lasting up to 13 weeks where participants receive an intravenous loading dose of claseprubart followed by subcutaneous injections every two weeks. Part B is a randomized, double-blind period lasting up to 52 weeks where participants who responded in Part A receive either claseprubart or placebo as subcutaneous injections every two weeks. Eligible participants may then join an optional open-label extension lasting up to 104 weeks receiving claseprubart injections every two weeks. A safety follow-up period of 40 weeks follows to monitor long-term effects. Participants will undergo various assessments throughout the study, including evaluations of neurological function and disease activity using scales such as the Adjusted Inflammatory Neuropathy Cause and Treatment INCAT score, Inflammatory Rasch-built Overall Disability Scale I-RODS, grip strength measurements, and other strength and disability scales. Researchers will also monitor for adverse events, measure serum drug concentrations, and evaluate immune responses. The total participation time may extend over several years, with regular visits for treatment administration, monitoring, and safety follow-up.
Actively Recruiting
Healthy Volunteer
Researchers are studying adults with Duchenne muscular dystrophy DMD, a genetic disorder that causes progressive muscle weakness and complications like respiratory and heart problems, osteoporosis, and fractures. The study aims to better understand bone health issues in this population by examining the prevalence of fragility fractures, childhood risk factors, fracture treatments, bone metabolism markers, and genetic factors linked to fracture risk. About 200 adults with DMD aged 18 to 44 will be recruited from specialized centers, along with a control group of healthy males over 18 who will provide blood samples. Participants with DMD will undergo respiratory and orthopedic assessments, motor and upper-limb function tests, walking capacity evaluation, spine X-rays, and bone density scans. Blood samples will be collected for biochemical and genetic analyses. During the study, clinical history and medical data will be collected and anonymized. Researchers will analyze bone health, fracture prevalence, treatment patterns, and related biochemical and genetic markers. The study will measure lung function, spinal deformities, motor abilities, and bone density. The findings aim to improve fracture prevention and bone health management in adults with DMD. Participation involves assessments and sample collection at specialized centers, with data protection ensured.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of masitinib combined with riluzole compared to a placebo combined with riluzole for treating Amyotrophic Lateral Sclerosis ALS. This phase 3 study focuses on patients diagnosed with probable or definite ALS, aiming to understand how masitinib, a drug that targets cells involved in neuroinflammation, might slow disease progression and affect the nervous systems environment. Participants receive oral masitinib at 3.0 mgkgday twice daily, with dose increases to 4.5 mgkgday after 4 weeks, and for some, an additional increase to 6.0 mgkgday after another 4 weeks. Each dose increase includes safety monitoring. Masitinib is given alongside riluzole, a standard ALS treatment at 50 mg twice daily. The control group receives a matching placebo with riluzole. The study is randomized, double-blind, and includes two different masitinib dose escalation schedules. During the 48-week study period, participants undergo regular assessments including functional rating scales ALSFRS-R, quality of life questionnaires ALSAQ-40, survival and progression monitoring, lung function tests FVC, and muscle strength measurements HHD. Researchers measure changes in combined function and survival scores. Safety is closely monitored throughout, with follow-up extending up to 36 months for disease progression or death. Total participation includes baseline screening, treatment, and long-term observation.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of zeleciment basivarsen DYNE-101 for treating myotonic dystrophy type 1 DM1. This phase 3 study includes participants diagnosed with DM1 confirmed by genetic testing and aims to assess the impact of DYNE-101 on physical function and disease symptoms. Participants are randomly assigned to receive either DYNE-101 or a matching placebo through intravenous infusion every 8 weeks during a 48-week placebo-controlled period. Following this, all participants enter a 24-week long-term extension where those initially on placebo switch to DYNE-101, and those on DYNE-101 continue the treatment. An Independent Data Monitoring Committee oversees safety and tolerability throughout the study. Participants undergo evaluations including the 5 Times Sit-To-Stand test as the primary outcome and various secondary measures such as hand opening time, muscle strength tests, walking speed, and patient and clinician global impressions. Blood samples are collected to monitor drug levels and immune responses. The total participation time may last up to approximately 80 weeks, including screening, treatment, and long-term follow-up assessments.
Actively Recruiting
Researchers are conducting a global, multicenter, and long-term observational study called the Pompe Disease Registry to track the natural history and outcomes of Pompe disease in patients, whether they are receiving treatment or not. This registry aims to improve understanding of the diseases variability, progression, and identification to better guide therapeutic interventions and patient care. The registry collects data from patients diagnosed with Pompe disease to characterize the disease population and evaluate the long-term effectiveness of alglucosidase alfa. It serves multiple purposes, including fulfilling regulatory commitments, supporting product development and reimbursement, and enabling other research and non-research uses. Participants provide information over many years, up to 30 years, helping researchers understand the diseases manifestations and progression. The registry gathers data that assists the medical community in developing monitoring recommendations and producing patient outcome reports to optimize care. Participation involves ongoing data collection but does not include experimental treatments or interventions.